Creating a new weapon in the fight against malaria

May 8, 2012

Over 200 million people contract malaria each year, and according to the World Health Organization, an estimated 655,000 people died from malaria in 2010.

Malaria is caused by the parasite Plasmodium, which is transmitted to humans through mosquito bites. More effective control of malaria will require the development of to prevent new infections.

Wesley Van Voorhis at the University of Washington in Seattle and Oliver Billker at the Wellcome Trust Sanger Institute in Cambridge, England assembled an international research team to tackle the challenge of finding new ways to combat malaria.

Their unique approach was to uncover a pathway that could block transmission of Plasmodium from humans to mosquitos, which represents a new strategy for controlling the spread of malaria.

They discovered a new class of malaria transmission-blocking compounds that work by inhibiting a protein known as bumped kinase I. Bumped kinase I is required for Plasmodium to transition to sporozoites stage, the stage in its life cycle when it is infectious to mammals. In that fed on blood treated with the bumped kinase inhibitor, Plasmodium sporozoite formation was blocked.

The research team showed preclinical data in mice indicating that bumped kinase inhibitors are safe and well tolerated.

Their results show that bumped kinase inhibitors target a new life cycle stage in Plasmodium, and suggest that these compounds merit further development as a new therapy for .

Explore further: Wolbachia bacteria reduce parasite levels and kill the mosquito that spreads malaria

More information: www.jci.org/articles/view/61822?key=bd73a892f008d6fa9cae

Related Stories

Slamming the brakes on the malaria life cycle

February 23, 2012

Scientists have discovered a new target in their fight against the devastating global disease 'malaria' thanks to the discovery of a new protein involved in the parasite's life cycle.

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.